Vividion Therapeutics

Proprietary Screening

Additional undisclosed programs RD/Clin0 IBD, oncology, immunology conditions

Vividion Therapeutics is developing selective small molecules for cancer and immune disorders. Despite technical advances, about 90% of disease-causing proteins cannot be targeted with therapeutics because effective binding sites have not been found. To find previously unknown and functional protein binding pockets and small molecules that bind them, Vividion is using their chemoproteomic platform technology. The platform addresses key limitations of conventional screening techniques through the use of expertise in chemistry, biology and drug development. Vividion is advancing a diversified pipeline with lead programs targeting NRF2, STAT3 and WRN, all disease-causing proteins in oncology and immunology.